Health Care • Biotechnology: Pharmaceutical Preparations
$6.81 ▲ +0.50
(+7.92%)
MKT CAP: $247.1M • VOL: 1.15M
52W L $5 52W H $33
EVMN // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $13.0M | $7.0M |
| YoY Revenue Growth % | +85.7% | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$81.1M | -$70.0M |
| Operating Margin % | -80.0% | -80.0% |
| Net Income (GAAP) | -$68.9M | -$66.8M |
| EBITDA (Normalized) | -$80.9M | -$69.9M |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$76.4M | -$58.2M |
| Capital Expenditures (CapEx) | $235.0K | $88.0K |
| Free Cash Flow (FCF) | -$76.7M | -$58.3M |
| FCF Margin % | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -39.7% | -45.0% |
| Cash & Short-Term Equivalents | $44.1M | $16.3M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $205.6M | -$144.2M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR EVMN.